Immunic (IMUX) Stock Price
Immunic Price
Analysts set a median price target of 20.50 USD, implying 194.1% above the current price. Of 18 analysts, 17 rate the stock a buy — an overall Buy consensus.
Immunic stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Immunic business model & stock analysis
Frequently asked questions about Immunic
Immunic Inc is primarily present in the United States.
Immunic Inc represents a strong commitment to advancing the treatment of autoimmune diseases and chronic inflammatory conditions. The company's corporate philosophy is centered around pioneering innovative therapies that address unmet medical needs, backed by extensive research and development. Immunic Inc prioritizes patient-centricity, aiming to enhance quality of life through effective and safe treatment options. With a focus on excellence and scientific rigor, Immunic Inc strives to deliver groundbreaking therapies that can make a meaningful difference in patients' lives.
The business model of Immunic Inc. is focused on developing innovative therapies for chronic inflammatory and autoimmune diseases. The company aims to leverage its deep understanding of the immune system and expertise in small molecule drug development to create potential treatments that target specific diseases. Through its research and development efforts, Immunic Inc. seeks to address unmet medical needs and improve the lives of patients suffering from a range of disorders, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. By combining scientific knowledge with a patient-centered approach, the company strives to provide effective and accessible therapies in the field of immunology.
Immunic Inc is primarily active in the pharmaceutical industry.
The main competitors of Immunic Inc in the market are [insert competitor names here].
Immunic Inc. is a pharmaceutical company specializing in the development of innovative therapies for autoimmune diseases and chronic inflammatory disorders. Founded in 2016, Immunic Inc. has quickly emerged as a key player in the field. The company is focused on leveraging its expertise in small molecule drug development to address unmet medical needs. Immunic Inc. is committed to advancing its pipeline of potential treatments, utilizing a targeted approach to modulate the immune system and provide patients with novel therapeutic options. With a strong dedication to research and development, Immunic Inc. aims to make a significant impact on patients' lives and contribute to the advancement of healthcare.
Immunic Inc, a leading biopharmaceutical company, has reached several significant milestones. Firstly, the company successfully completed a Phase 2 clinical trial for its novel therapeutic candidate, IMU-838, in patients with relapsing-remitting multiple sclerosis. The encouraging results demonstrated its potential in reducing disease activity and progression. Additionally, Immunic Inc achieved the initiation of Phase 2 clinical trials for IMU-935, an orally available small molecule targeting chronic inflammatory and autoimmune diseases. These milestones represent the company's commitment to developing innovative therapies addressing unmet medical needs. Immunic Inc continues to advance its pipeline, striving to provide effective treatments for patients globally.
Analysts currently set an average price target of 22.13 USD for the Immunic stock (median: 20.50 USD), implying +217.5 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the Immunic stock: 17 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Immunic to generate revenue of 12.50 M USD and earnings per share of -35.65 USD.
Converted at the current exchange rate, the Immunic share trades at 6.21 EUR (6.97 USD).
The Immunic share (IMUX) is listed on 5 stock exchanges, including: NASDAQ (IMUX), Frankfurt (10VA.F), München (10VA.MU), Düsseldorf (10VA.DU).
Immunic Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of immune and inflammatory diseases.The company's business model is based on four main pillars: research and development, clinical studies, product distribution, and partnerships.
The expected revenue of Immunic is 12.50 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Immunic is -429.18 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Immunic is currently -0.20. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Immunic stock.
The price-to-sales ratio (P/S) of Immunic is currently 6.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Immunic stock.
The Eulerpool Quality Score for Immunic is 2/10.
The ISIN of Immunic is US4525EP1011. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Immunic is A2PHD4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Immunic is IMUX. The ticker symbol is used to trade Immunic shares on the stock exchange.
Immunic stock
Immunic Peer Group
Immunic Ticker
Immunic FIGI
All fundamentals and in-depth analysis of Immunic
Our stock analysis for Immunic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.